ITRM: Iterum Therapeutics Quarterly EPS earnings growth

Public company logo of Iterum Therapeutics (ITRM)

Global demand for urinary tract infection treatments is steadily growing. The trend of quarterly earnings per share growth allows for an assessment of the real financial momentum of Iterum Therapeutics plc (ITRM), while the value of 0.00 reflects this status. The "last-resort" status of the drugs ensures business stability, and the commercialization of sulopenem will become the primary source of future revenue.

Iterum Therapeutics PLC (ITRM) - Year-over-year net earnings per share growth for the last 12 months from 07/04/2022 to 04/11/2026

Summary analytical data breakdowns for Iterum Therapeutics (ITRM)

- share price and expert price forecast:
Stock Price Iterum Therapeutics|ITRM - Forecast Levels Chart
- market capitalization information:
Market Capitalization Iterum Therapeutics, plc|ITRM - Total Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Iterum Therapeutics|ITRM - Company Net Assets|Market Cap to Net Assets Ratio iterumtx.com|ITRM - Aggregate Business Assets
- company liabilities and liquidity data:
Total Debt to Capital Iterum Therapeutics plc|ITRM - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity iterumtx.com|ITRM - Company Cumulative Debt|Debt to Book Capitalization Ratio Iterum Therapeutics PLC|ITRM - Company Long-Term Indebtedness|Company Short-Term Debt Iterum Therapeutics|Quick Ratio iterumtx.com
- earnings and valuation multiples indicators:
ITRM - Net Financial Result|Future Profit Iterum Therapeutics plc|ITRM - Market Price to Net Income Ratio|Forward P/E Multiple iterumtx.com|ITRM - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iterum Therapeutics plc|ITRM - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Iterum Therapeutics|ITRM - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months iterumtx.com|ITRM - Net earnings per share growth this year|Expected earnings per share growth for next year Iterum Therapeutics plc
- revenue and sales proceeds data:
ITRM - Company Sales Revenue|Company Future Sales Volume iterumtx.com|ITRM - Market Cap to Sales Volume|Forward P/S Multiple Iterum Therapeutics plc|ITRM - Revenue Dynamics YoY (Last Twelve Months)
Comprehensive company analysis:Iterum Therapeutics plc
Flagship merchandise of iterumtx.com

When screening issuer reliability, this indicator measures the growth rate of net earnings per share, allowing for an assessment of the business's real scaling momentum through the percentage ratio of current to previous quarterly results. On the GURU.Markets platform, the quarterly change in earnings per share reflects the commercial impact of patent protection for Iterum Therapeutics plc (ITRM) and its product Orlynvq, where the absence of generics should translate into sustained acceleration of financial growth.

Key competitors

SMMT: Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months MRNA (Moderna Corp)|PCVX (Vaxcyte Inc) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tarsus Pharmaceuticals TARS|Quarterly EPS earnings growth CRMD|Year-over-year net earnings per share growth for the last 12 months Seres MCRB|Spero Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months SCYX (Scynexis)|AN2 Therapeutics Inc - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months PolyPid PYPD|YS Biopharma (LSB) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months BiomX Ltd (PHGE)|Year-over-year earnings per share growth for the last twelve months Soligenix|Year-over-year earnings per share growth for the last 12 months SXTP (60degreespharma.com)|Year-over-year earnings per share growth for the last twelve months oragenics.com (OGEN)|Year-over-year net earnings per share change for the last twelve months opgen.com